Becton, Dickinson and Company Other income, net decreased by 32.0% to -$66.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 88.6%, from -$35.00M to -$66.00M. Over 4 years (FY 2021 to FY 2025), Other income, net shows a downward trend with a 16.7% CAGR.
other_other_operating_income_expense_net| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $88.00M | $0.00 | $4.00M | $0.00 | -$11.00M | -$30.00M | -$3.00M | -$4.00M | $13.00M | $203.00M | -$11.00M | $23.00M | -$98.00M | -$136.00M | -$28.00M | -$35.00M | -$38.00M | -$285.00M | -$50.00M | -$66.00M |
| QoQ Change | — | -100.0% | — | -100.0% | — | -172.7% | +90.0% | -33.3% | +425.0% | >999% | -105.4% | +309.1% | -526.1% | -38.8% | +79.4% | -25.0% | -8.6% | -650.0% | +82.5% | -32.0% |
| YoY Change | — | — | — | — | -112.5% | — | -175.0% | — | +218.2% | +776.7% | -266.7% | +675.0% | -853.8% | -167.0% | -154.5% | -252.2% | +61.2% | -109.6% | -78.6% | -88.6% |
| Segment | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Connected Care | — | — | — | — | — | — | — | -$3.00M |
| BioPharma Systems | — | — | — | — | — | — | — | $0.00 |
| Interventional | — | — | — | — | — | — | — | $0.00 |
| Life Sciences | -$1.50M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Medical Essentials | — | — | — | — | — | — | — | $0.00 |
| Total | $203.00M | -$11.00M | $23.00M | -$98.00M | -$136.00M | -$28.00M | -$50.00M | -$66.00M |
Medical is derived from annual filings.
Life Sciences was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.